Abstract 1137P
Background
Modern therapies have significantly improved outcome for patients with melanoma brain metastases (MBM). Still, the prognosis is poor, and the optimal treatment strategy is not well defined. Here, we report on the survival outcomes of systemic and locoregional treatments in an unselected, nationwide population-based cohort of patients with MBM.
Methods
All patients diagnosed with MBM in Denmark between 2015-2022 were retrospectively included. Patients were identified using the Danish Metastatic Melanoma Database (DAMMED) and local records of surgery and radiotherapy. Data were obtained from patient records.
Results
A total of 838 patients were included. Median overall survival (mOS) of the entire cohort was 9.0 months, and 112 patients were alive >3 years after diagnosis of MBM. Treatment with immune checkpoint inhibitors (ICI), ipilimumab + nivolumab, resulted in an intracranial overall response rate (icORR) of 46%, and a 2-year OS of 49% whereas BRAF/MEK-inhibitors (BRAF/MEKi) resulted in an icORR of 56%, and 2-year OS of 20%. A subgroup of patients with symptomatic MBM, treated initially with BRAF/MEKi with planned shift to ICI, had an icORR of 70%, 2-year OS of 50% and reached the longest mOS of 26 months. Patients with meningeal carcinomatosis (n=67) had a mOS of 8.4 months. Systemic therapy significantly improved OS for these patients, but no survival benefit was observed for patients receiving ICI compared to BRAF/MEKi. In total, 230 patients underwent surgery for MBM; of these, 30 received postoperative stereotactic radiosurgery (SRS). Baseline characteristics were balanced between the two groups. No benefit in OS or intracranial progression free survival was observed for patients receiving postoperative SRS.
Conclusions
Modern systemic therapies have improved survival for real-world patients with MBM; BRAF/MEKi had the highest icORR while ICI generated more durable responses. Planned shift from BRAF/MEKi to ICI can lead to long-term survival in selected patients. Postoperative SRS for patients undergoing surgery for MBM is questioned as a standard procedure.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
R.B. Friis: Non-Financial Interests, Personal, Other, Travel and conference expenses: MSD. M. Donia: Financial Interests, Personal, Invited Speaker, Teaching: Novartis, Roche; Financial Interests, Personal, Other, Advisor: Achilles Therapeutics; Non-Financial Interests, Other, Sub-investigator of clinical trial with connected translational research: Bristol Myers Squibb; Non-Financial Interests, Personal, Proprietary Information, Proprietary data access: Bristol Myers Squibb; Non-Financial Interests, Personal, Proprietary Information, Proprietary Data Access: Genentech; Other, Chairman of the Melanoma and Non-melanoma Skin Cancer Scientific Committee: Danish Medicines Council (Medicinrådet). C.A. Haslund: Financial Interests, Personal, Invited Speaker: MSD, GSK, BMS; Financial Interests, Institutional, Local PI: BMS, Tesaro, MSD, IO Biotech, Chimerix, Incyte; Financial Interests, Institutional, Coordinating PI: GSK, Celgene Aps. H. Schmidt: Other, Institutional, Other: Danish Medicines Council, Member of the Melanoma and Non-Melanoma Skin Cancer Scientific Committee. L. Bastholt: Non-Financial Interests, Advisory Role, Scientific committee under Danish Medicines Agency regarding new Treatments of Melanoma, Skin Cancer and Thyroid Cancer: Danish Medicines Agency. I. Svane: Financial Interests, Personal, Advisory Board: BMS, Pierre Fabre, Novartis; Financial Interests, Personal, Invited Speaker: MSD, Pierre Fabre, Novartis, Roche, BMS; Financial Interests, Personal, Writing Engagement: MSD; Financial Interests, Personal, Stocks/Shares, Cofounder and Founder Warrants: IO Biotech; Financial Interests, Institutional, Research Grant: Adaptimmune, Enara Bio, Lytix Biopharma, TILT Biotherapeutics; Financial Interests, Institutional, Funding: Evaxion; Non-Financial Interests, Principal Investigator: BMS, Novartis, Roche, TILT Biotherapeutics, Lytix Biopharma. E. Ellebæk: Financial Interests, Personal, Invited Speaker: Pierre Fabre, BMS, Novartis, MSD, Pfizer; Other, Travel and conference expenses: MSD, Pierre Fabre. All other authors have declared no conflicts of interest.
Resources from the same session
1160P - Methods of nivolumab administration in advanced melanoma: A comparison of patients’ clinical outcomes treated with flat dose or weight-adjusted dose, FLATIMEL study
Presenter: Iona Campo le Brun
Session: Poster session 13
1161P - Therapeutic outcome of molecular profiling of melanoma patients resistant to standard treatment: Real-world data
Presenter: Madona SAKKAL
Session: Poster session 13
1162P - Prolonged exposure to proton pump inhibitors (PPI) at the time of initiation of immune checkpoint blockade (ICB) mediates better clinical outcomes in patients with metastatic melanoma
Presenter: Kyrillus Shohdy
Session: Poster session 13
1163P - CD39 affect the prognostic role of NLR via N2 neutrophils in metastatic melanoma patients treated with immunotherapy
Presenter: Domenico Mallardo
Session: Poster session 13
1164P - Changes of TCR repertoire in metastatic melanoma and renal cell carcinoma patients treated with nivolumab correlate with overall survival
Presenter: Martin Klabusay
Session: Poster session 13
1165P - Single cell spatial features of in-transit melanoma associated with patient outcome to immunotherapy
Presenter: Xinyu Bai
Session: Poster session 13
1166P - Multi-modal and longitudinal characterization of the tumor and immune microenvironment from primary melanoma to in-transit and distant metastasis
Presenter: Giuseppe Tarantino
Session: Poster session 13
1168P - Tumor PD-L1 predicts the outcome of PD-1-based immunotherapy in metastatic melanoma depending on the type of tissue examined
Presenter: Jan-Malte Placke
Session: Poster session 13
1169P - Tumour transcriptional and spatial protein profiling in Mexican patients reveals that acral lentiginous melanoma is characterized by an immunosuppressive microenvironment
Presenter: Martha Estefania Vázquez-Cruz
Session: Poster session 13
1170P - Survival outcome prediction of primary melanoma tumours from histology images using deep learning
Presenter: Céline Bossard
Session: Poster session 13